RBNAX Holdings — Robinson Opportunistic Income Fund

All 44 reported holdings of Robinson Opportunistic Income Fund (RBNAX) by percentage of net assets, from the fund's latest SEC N-PORT filing.

Holding% of net assetsValue (USD)
Flaherty & Crumrine Preferred5.97%$636.25K
FS Credit Opportunities Corp5.62%$598.80K
FS Specialty Lending Fund5.56%$592.35K
DoubleLine Yield Opportunities5.52%$588.11K
Western Asset Global High Inco5.50%$586.52K
KKR Income Opportunities Fund5.47%$583.14K
Western Asset High Income Fund5.45%$581.33K
BlackRock Multi-Sector Income5.43%$579.16K
Western Asset Inflation-Linked5.40%$575.40K
Western Asset Mortgage Opportu5.37%$571.83K
Nuveen Floating Rate Income Fu5.28%$563.09K
Credit Suisse High Yield Credi4.89%$520.85K
XAI Floating Rate & Alternativ4.66%$496.67K
Invesco Senior Income Trust4.62%$491.86K
John Hancock Investors Trust3.48%$370.42K
Principal Real Estate Income F2.49%$265.05K
Brookfield Real Assets Income2.37%$252.47K
Western Asset Inflation-Linked2.36%$251.71K
Neuberger High Yield Strategie1.91%$203.38K
Umb Ib Money Market Ii /1.44%$153.43K
Sprott Physical Gold and Silve1.32%$141.21K
ASA Gold and Precious Metals L1.32%$141.03K
McKinley Acquisition Corp1.14%$121.98K
FG Imperii Acquisition Corp1.14%$121.08K
Apex Treasury Corp1.13%$120.60K
Saba Capital Income & Opportun0.99%$105.46K
Drugs Made In America Acquisit0.94%$100.60K
Bitcoin Infrastructure Acquisi0.94%$100.00K
Origin Investment Corp I0.48%$51.50K
Apex Treasury Corp.-Cl A0.02%$1.95K
E-Mini Russ 1000 VSe SEPT 26 /0.02%$1.69K
Estrella Immunopharma, Inc.0.02%$1.61K
Bitcoin Infrastructure-Cl A0.01%$1.56K
Alchemy Investments Acquisit0.01%$1.26K
Qt Imaging Holdings, Inc.0.01%$979
Drugs Made In America Acquisit0.01%$727
Stardust Power, Inc.0.00%$408
Origin Investment Corp. I0.00%$317
Escrow Placeholder Acropolis Infrastruc /0.00%$0
Bowen Acquisition Corp0.00%$0
Electriq Power Holdings, Inc.0.00%$0
10 Yr T-Note Future September 2026 /-0.01%$-1.45K
E-Mini Dow Sept 26 /-0.02%$-2.08K
U.s. T-Bond 30yr September 2026 /-0.05%$-4.92K

RBNAX overview: performance, fees, allocation and SEC filings